

# MEDICINES NOTIFICATION

## CLASS 2 MEDICINES RECALL, EL(26)A/18

Action within 48 hours

Issued 30 March 2026

Distribute to Pharmacy/Wholesaler Level

### MARKETING AUTHORISATION HOLDER (MAH)

Bio Products Laboratory Limited

### MEDICINE DETAILS

**Rabies, Human normal Immunoglobulin 500IU solution for Injection**

PL: 08801/0014

Active Ingredient: Human Rabies Immunoglobulin

SNOMED code: 422303009

GTIN: 15019943000352

### AFFECTED LOT BATCH NUMBERS

Batch No.	Expiry Date	Pack Size	First Distributed
JRC24208	April 2027	500 IU	October 2024

## Background

Bio Products Laboratory Limited is recalling one batch of Human Rabies Immunoglobulin following a stability failure for this batch. The batch has shown a reduction in potency of the Human Rabies immunoglobulin. This action is intended to prevent any potential reduction in clinical effectiveness of the product. No adverse event reports have been received related to this defect.

This recall does not impact other batches manufactured that are currently on the market.

### Advice for Healthcare Professionals:

Stop supplying the above batch immediately. Quarantine all stock and return it to your supplier using your supplier's approved process.

Bio Products Laboratory Limited can confirm that 1,414 packs of this batch have been released and distributed. No related adverse event reports have been received related to this defect.

### Advice for Healthcare Professionals to Provide to Patients:

No action is required by patients as this product is administered by healthcare professionals only, who will ensure the affected stock is removed from use.

The recall is a precautionary measure to mitigate the risk of a loss of efficacy of the product once administered. No adverse event reports have been received related to this issue. Patients who may have received treatment from these batches will not need to take any action.

Patients who experience adverse reactions or have any questions about the medication should seek medical attention. Any suspected adverse reactions should also be reported via the [MHRA Yellow Card scheme](#).

### Additional information:

For all medical information enquiries and information on this product, please email [medinfo@bpl.co.uk](mailto:medinfo@bpl.co.uk) or [medinfo@kedrion.com](mailto:medinfo@kedrion.com) or telephone +44 (0)20 89572255, +44 (0)20 89572622 or +44 (0)20 89572200

For stock control enquiries please email [bplorders@kedrion.com](mailto:bplorders@kedrion.com), or telephone +44 (0)20 89572251

Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Yours faithfully

**Defective Medicines Report Centre**  
**10 South Colonnade, Canary Wharf**  
**London, E14 4PU**

**Telephone +44 (0)20 3080 6574**

[DMRC@mhra.gov.uk](mailto:DMRC@mhra.gov.uk)